Omnitram Safety and Efficacy in the Treatment of Diabetic Neuropathy
Status:
Completed
Trial end date:
2020-08-17
Target enrollment:
Participant gender:
Summary
This study evaluates the analgesic effect of Omnitram for the treatment of painful diabetic
neuropathy. Each subject with diabetic neuropathy will be treated for four weeks with
Omnitram and for four weeks with placebo. The order of the Omnitram and placebo treatment
will be random.
Phase:
Phase 2
Details
Lead Sponsor:
Syntrix Biosystems, Inc.
Collaborators:
DF/Net Research National Institute on Drug Abuse (NIDA)